The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Ischemix Inc., a biotechnology company that develops cytoprotective compounds to treat advanced renal and cardiovascular conditions, made an announcement today that it has appointed David A. DeWahl, Jr. as its new President and CEO.
Ischemix Inc., a biotechnology company that develops cytoprotective compounds to treat advanced renal and cardiovascular conditions, made an announcement today that it has appointed David A. DeWahl, Jr. as its new President and CEO.
As quoted in the press release:
“We are extremely pleased to welcome Mr. DeWahl as our CEO. His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Reinier Beeuwkes, Ph.D., Chairman of the Board and Chief Scientific Officer of the Company.
Latest News
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2303.91 | -29.16 | |
| Silver | 26.42 | -0.66 | |
| Copper | 4.57 | -0.11 | |
| Oil | 82.25 | -0.38 | |
| Heating Oil | 2.53 | -0.01 | |
| Natural Gas | 2.05 | +0.02 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.